Literature DB >> 6438349

Effects of GM1 ganglioside on developing and mature serotonin and noradrenaline neurons lesioned by selective neurotoxins.

G Jonsson, A Gorio, H Hallman, D Janigro, H Kojima, J Luthman, R Zanoni.   

Abstract

The effect of exogenous GM1 ganglioside on selective neurotoxin-induced lesions of serotonin (5-HT) and noradrenaline (NA) neurons in both the central and peripheral nervous systems has been investigated in developing and adult rats and mice by employing neuro- and histochemical techniques. 5,7-Dihydroxytryptamine (5,7-HT) was used to lesion 5-HT neurons, and 6-hydroxydopamine (6-OH-DA) was used to lesion NA neurons. In most lesion models investigated the neurotoxin causes primarily an axonal nerve terminal damage without notably affecting the perikarya. There was no evidence indicating that GM1 interferes with the primary and direct neurodegenerative actions of 5,7-HT or 6-OH-DA on 5-HT and NA nerve terminals, respectively. In all lesion models GM1 had in the chronic stage a counteracting effect on the neurotoxin-induced nerve terminal lesion or enhanced regrowth. The present results are compatible with the view that GM1 has a regrowth-stimulating effect and/or protective actions against secondary retrograde degeneration following the initial nerve terminal lesion induced by the neurotoxin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6438349     DOI: 10.1002/jnr.490120229

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

1.  Impaired axonal transport of acetylcholinesterase in the sciatic nerve of alloxan-diabetic rats: effect of ganglioside treatment.

Authors:  P Marini; M Vitadello; R Bianchi; C Triban; A Gorio
Journal:  Diabetologia       Date:  1986-04       Impact factor: 10.122

2.  Exogenous gangliosides may affect methylation mechanisms in neuronal cell cultures.

Authors:  B Ferret; A Hubsch; H Dreyfus; R Massarelli
Journal:  Neurochem Res       Date:  1991-02       Impact factor: 3.996

3.  GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Authors:  Jay S Schneider; Franca Cambi; Stephen M Gollomp; Hiroto Kuwabara; James R Brašić; Benjamin Leiby; Stephanie Sendek; Dean F Wong
Journal:  J Neurol Sci       Date:  2015-06-16       Impact factor: 3.181

4.  The Therapeutic Role of Gangliosides in Neurological Disorders.

Authors:  J S Schneider
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

Review 5.  Is ganglioside GM1 effective in the treatment of stroke?

Authors:  S Braune
Journal:  Drugs Aging       Date:  1991-01       Impact factor: 3.923

Review 6.  Ganglioside function in the development and repair of the nervous system. From basic science to clinical application.

Authors:  S D Skaper; A Leon; G Toffano
Journal:  Mol Neurobiol       Date:  1989       Impact factor: 5.590

7.  A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Authors:  Jay S Schneider; Stephen M Gollomp; Stephanie Sendek; Amy Colcher; Franca Cambi; Wei Du
Journal:  J Neurol Sci       Date:  2012-11-28       Impact factor: 3.181

8.  Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.

Authors:  Jay S Schneider; Thomas N Seyfried; Hyo-S Choi; Sarah K Kidd
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

9.  Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease.

Authors:  Jay S Schneider
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.